17 No source found (not proven false)
There are 18 to 19 different subspecies of Bartonella.
"Now, there are 18 to 19 different subspecies of Bartonella." (said at 0:08:31)
No published record matching the claim that there are 18 to 19 different subspecies of Bartonella was located; this does not prove the claim false.
Hard tick relapsing fever Borrelia, such as Borrelia miyamotoi, is found in 25% of chronically ill Lyme-like patients.
"there's a relapsing fever Borrelia. It's like a cousin of Lyme disease. It's also showing up in 25% of these patients." (said at 0:10:54)
No published record matching the claim that hard tick relapsing fever Borrelia (such as Borrelia miyamotoi) is found in 25% of chronically ill Lyme-like patients was located; this does not prove the claim false. Published seroprevalence surveys in cohorts with chronic, complex, or Lyme-like illnesses report variable and distinct seropositivity rates (for example, approximately 10% standard Borrelia seropositivity in Canadian chronic illness cohorts), but do not corroborate a 25% detection rate for relapsing fever Borrelia species.
Lyme and Bartonella destroy bone marrow B cells, resulting in common variable immune deficiency in 20% of patients and IgG subclass deficiency in 85%.
"you get Lyme and Bartonella, which causes immune deficiency. So it destroys your B cells from the bone marrow that make antibodies. 20% of my patients come in with common variable immune deficiency, 85% subclass deficiency." (said at 0:11:39)
No published record matching the claim that Lyme disease and Bartonella infection destroy bone marrow B cells to cause common variable immunodeficiency in 20% of patients or IgG subclass deficiency in 85% of patients was located; this does not prove the claim false.
Mitochondria are responsible for producing approximately 90% of the energy in the human body.
"Now, mitochondria are responsible for producing about 90% of the energy in your body." (said at 0:13:26)
No published record matching the claim that mitochondria are responsible for producing approximately 90% of the energy in the human body was located; this does not prove the claim false.
Up to 20% of chronically ill patients are deficient in intracellular red blood cell zinc, copper, and magnesium.
"When we look intracellularly at the red blood cell zinc, the red blood cell copper, the red blood cell magnesium, we're finding up to 20% of our patients are deficient, which means you cannot detoxify properly and deal with inflammation." (said at 0:23:18)
No published record matching the claim that up to 20% of chronically ill patients are deficient in intracellular red blood cell zinc, copper, and magnesium was located; this does not prove the claim false.
Testing data from Function Health shows that 70% of individuals are deficient in one or more nutrients based on standard lab reference ranges.
"with Function Health, a company I co-founded, now we have over half a million members, we've done over 100 million lab tests. 70% of people are deficient in one or more nutrient, not at the level you or I would think would be okay, but at the level the lab reference range thinks is okay" (said at 0:25:15)
No published record matching the claimed testing data from Function Health showing that 70% of individuals are deficient in one or more nutrients based on standard laboratory reference ranges was located; this does not prove the claim false. The cited figure appears to reflect unpublished internal customer data from a commercial testing company rather than peer-reviewed epidemiological research.
A published paper in Journal of Alzheimer's Disease Reports demonstrated complete reversal of the Alzheimer's biomarker p-tau217 following dapsone combination therapy.
"I recently published an article in the Journal of Alzheimer's Disease Reports... I reversed for the first time ever in the world the most sensitive and specific biomarker for Alzheimer's, p-tau217... when we treated the Lyme disease with the 9 weeks of dapsone combination therapy... completely reversed p-tau217." (said at 0:28:33)
No published record matching the claim of complete reversal of the p-tau217 biomarker following dapsone combination therapy in the Journal of Alzheimer's Disease Reports was located; this does not prove the claim false.
Bartonella infection induces vascular endothelial growth factor (VEGF) elevation in long COVID patients.
"And a lot of these long COVID patients who come in with VEGF, with vascular endothelial growth factor, it's not from spike proteins that are actually inflaming the endovascular area, it's basically Bartonella." (said at 0:08:55)
No published record matching the claim that Bartonella infection is the primary cause of vascular endothelial growth factor (VEGF) elevation in long COVID patients was located; this does not prove the claim false. Published literature demonstrates that Bartonella species produce factors (such as the autotransporter BafA) that activate VEGF receptors and stimulate angiogenesis (e.g., PMID 32678094), and elevated VEGF-A expression has been documented in cohorts of patients with long COVID (e.g., PMID 41074076). Additionally, isolated case reports note that Bartonella infections can clinically mimic or coincide with long COVID symptoms (PMID 38472519). However, no clinical or epidemiological study has demonstrated that elevated VEGF in long COVID cohorts is attributable to underlying Bartonella infection.
- context: The Bartonella autotransporter BafA activates the host VEGF pathway to drive angiogenesis. (Nature communications 2020) · cited 41x in the literature
"BafA interacts with vascular endothelial growth factor (VEGF) receptor-2 and activates the downstream signaling pathway, suggesting that BafA functions as a VEGF analog." (abstract, passage verified)
pubmedfull study (doi) - context: Unmasking Bartonella henselae infection in the shadows of long COVID thanks to clinical me… (European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2024) · cited 6x in the literature
"This case study illustrates how investigating long COVID uncovered an underlying bartonellosis through clinical metagenomics. Following mild COVID-19, a 26-year-old woman experienced persistent symptoms during 5 months, including axillary adenopathy." (abstract, passage verified)
pubmedfull study (doi) - context: VEGFA sex-specific signature is associated to long COVID symptom persistence. (BMC medicine 2025) · cited 4x in the literature
"Findings revealed VEGFA overexpression in long COVID patients (effect size 0.322, SE = 0.098, p = 0.0013), along with sex-specific expression patterns and the influence of sex-hormonal status in females, with significant overexpression of circulating VEGFA levels specifically in postmenopausal women" (abstract, results, passage verified)
pubmedfull study (doi)
In a 2016 published study of 100 patients on low-dose dapsone, fatigue, joint pain, neuropathy, and brain fog showed statistically significant improvement, while headaches did not.
"I published my first article 2016 on 100 patients on low-dose dapsone. Fatigue got better, joint pain got better, neuropathy got better, brain fog; headaches was the only thing statistically that didn't improve." (said at 0:34:55)
No published record matching a 2016 study of 100 patients evaluating low-dose dapsone combination therapy for chronic Lyme disease symptoms was located; this does not prove the claim false. Subsequent retrospective observational analyses by the author evaluated cohorts of 200 patients receiving dapsone combination therapy, reporting improvements across several chronic symptom categories.
A study published by Tufts University showed that a combination of rifampin and dapsone cures Lyme disease in an animal model.
"Tufts, by the way, published one that showed that this combination rifampin/dapsone cures Lyme in the animal model." (said at 0:39:35)
No published record matching the claim that a study from Tufts University demonstrated a combination of rifampin and dapsone cures Lyme disease in an animal model was located; this does not prove the claim false. Published studies on dapsone combinations for Borrelia burgdorferi infection include in vitro evaluation of antibiotic combinations against stationary-phase or biofilm forms (such as PMIDs 32993780 and 28327498) and human case reports, but no study from Tufts University demonstrating cure in an animal model was identified in the published literature.
Exogenous testosterone injections cause testicular atrophy of approximately 15% and suppress endogenous hormone production.
"These testosterone shots are shrinking your testicles by 15%, and they're stopping your own hormone production." (said at 0:41:55)
No published record matching the claim that testosterone shots shrink testicles by approximately 15% while halting endogenous hormone production was located in the retrieved records; this does not prove the claim false.
A 9-week dapsone combination protocol reduced phosphorylated tau (p-tau217) levels by 63% in a patient.
"I lowered it by 63% in 9 weeks. And that was because it was the infection driving the amyloid and the phosphorylated tau." (said at 0:30:35)
No published record matching the claim that a 9-week dapsone combination protocol reduced phosphorylated tau (p-tau217) levels by 63% in a patient was located; this does not prove the claim false. While published clinical studies and case series on dapsone combination protocols in chronic Lyme disease and post-treatment Lyme disease syndrome exist (e.g., PMID 38792737, PMID 37764145, PMID 35884166, PMID 33105645), none of these published reports document or report data on p-tau217 reductions or tau biomarker changes associated with dapsone therapy.
Mycotoxins act as mitochondrial poisons, impair the immune system, and cause fatigue, brain fog, pain, and neuropathy.
"And the problem is that they're mitochondrial poisons and they're affecting your immune system and they cause fatigue, brain fog, pain, neuropathy." (said at 1:01:19)
No published record matching the claim that mycotoxins act as mitochondrial poisons, impair the immune system, and directly cause fatigue, brain fog, pain, and neuropathy in humans was located; this does not prove the claim false.
A case report published in the Journal of Alzheimer's Disease Reports in April 2024 showed that an oral antibiotic regimen normalized the p-tau 217 biomarker by 63% in nine weeks.
"It's in the Journal of Alzheimer's Disease Reports, April 2024. So anyone can read it. But what astonished me is this p-tau 217, which most neurologists consider to be the most sensitive and specific biomarker, I reversed it completely to normal by 63% in nine weeks with an oral antibiotic regimen." (said at 1:13:22)
No published record matching the reported April 2024 case report in the Journal of Alzheimer's Disease Reports describing a 63% normalization of the p-tau 217 biomarker in nine weeks following an oral antibiotic regimen was located; this does not prove the claim false.
In a study of 375 patients, dapsone combination therapy statistically improved patients' memory as its primary effect.
"But here's the beauty is dapsone combination therapy, the number one effect it always had was improving people's memory statistically in these 375 patients." (said at 1:13:40)
No published record matching a study of 375 patients evaluating dapsone combination therapy with statistically improved memory as its primary effect was located; this does not prove the claim false. Published retrospective chart reviews and observational cohorts on dapsone combination therapy in chronic Lyme disease/post-treatment Lyme disease syndrome report cohorts of 200 patients (evaluating eight general symptom categories without isolating memory as a primary endpoint), 40 patients, and 25 patients, rather than 375 patients.
The Center for Medicare & Medicaid Innovation established a 100 million dollar grant to study functional and lifestyle medicine for chronic illness.
"there's a grant that was established through the HHS innovation department, Medicare, Center for Medicare & Medicaid Innovation, for $100 million to study functional and lifestyle medicine for chronic illness." (said at 1:08:25)
No published record matching the claim that the Center for Medicare & Medicaid Innovation established a $100 million grant specifically to study functional and lifestyle medicine for chronic illness was located; this does not prove the claim false.
Approximately 25 percent of mycotoxins detected in human testing originate from dietary food sources.
"There are food mycotoxins, about 25% are probably coming from foods also." (said at 1:03:40)
No published record matching the claim that approximately 25 percent of mycotoxins detected in human testing originate from dietary food sources was located; this does not prove the claim false. In toxicology and public health biomonitoring, diet (e.g., consumption of contaminated grains, nuts, spices, and cereals) is widely recognized as the predominant route of human exposure to regulated mycotoxins such as deoxynivalenol, ochratoxin A, and aflatoxins, but no validated scientific ratio establishes a fixed 25% dietary contribution versus other routes.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.